Metsera (NASDAQ:MTSR) Sets New 1-Year Low – Here’s Why

Metsera, Inc. (NASDAQ:MTSR)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as $24.70 and last traded at $25.14, with a volume of 233191 shares changing hands. The stock had previously closed at $27.21.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MTSR. Evercore ISI began coverage on shares of Metsera in a research report on Tuesday. They issued an “outperform” rating for the company. Guggenheim began coverage on shares of Metsera in a research report on Tuesday. They issued a “buy” rating and a $56.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Metsera in a research report on Tuesday. They issued an “overweight” rating for the company. Finally, Bank of America began coverage on shares of Metsera in a research report on Tuesday. They issued a “buy” rating and a $38.00 price objective for the company.

Metsera Stock Down 0.9 %

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.